Antonio Frontera

⚡ #EHRATopicWeek on Atrial Tachycardias Catheter ablation has become the preferred treatment strategy for most symptomatic or recurrent ATs, while antiarrhythmic drug therapy often shows limited long-term efficacy. 📌 Key concepts from the latest evidence: • Beta-blockers and calcium channel blockers remain important for rate control • Catheter ablation is now first-line in many patients • High-resolution electroanatomical mapping has transformed our understanding of AT circuits • Entrainment and activation mapping remain essential tools for distinguishing focal vs reentrant mechanisms • Pulsed-field ablation and ultra-high-resolution mapping are opening a new era in AT treatment 💡 Success in AT ablation depends on identifying the “critical isthmus” — the key region maintaining the arrhythmia — while durable bidirectional block is increasingly recognized as a crucial procedural endpoint. Importantly, recurrence remains a major challenge, especially in patients with structural heart disease, prior AF ablation, or extensive atrial scarring Find out more in the #EHRA_ESC Consensus document on Atrial Tachycardias 👉bit.ly/4wk5sBn @escardio @EuropaceEiC

🔍 #EHRATopicWeek on Atrial Tachycardias Atrial Tachycardia is more complex than we once thought Traditionally, rapid regular atrial arrhythmias were divided into “atrial tachycardia” and “atrial flutter” based mainly on ECG appearance. Today, high-resolution mapping shows these distinctions are often oversimplified. 📌 Current concepts classify all regular atrial rhythms >100 bpm as AT: • Non-reentrant AT • Reentrant AT (localized or macro-reentrant) Importantly, many arrhythmias previously labeled as “flutter” may actually represent different AT mechanisms. ⚡ Differentiating AT from organized AF can be challenging, especially in scarred atria or after ablation. ECGs, EP studies, intracardiac mapping, and even wearable devices all play an important role in diagnosis. 💡 Precise classification matters — for diagnosis, treatment strategy, and improving ablation outcomes. Find out more in the #EHRA_ESC Consensus document on Management of patients with atrial tachycardia 🔗bit.ly/4wk5sBn @escardio @EuropaceEiC